Fig. 5.
TAT-Cx43266–283 enhances the survival of immunocompetent mice bearing GL261-GSC-derived gliomas. (A) Western blot and quantification of Y416 Src, total Src, Sox2, and GFAP in GL261-GSCs and GL261 (Dulbecco’s modified Eagle’s medium + fetal calf serum for 7 days); means ± SEM; n = 8 (Student’s t-test: ***P < 0.001). (B) Western blot of Y416 Src, total Src, Sox2, and glyceraldehyde 3-phosphate dehydrogenase in GL261-GSCs control or treated with 50 µM TAT-Cx43266–283 for 24 h. (C) GL261-GSCs together with 100 µM TAT-Cx43266–283 or saline were intracranially injected in C57BL/6 mice. After 7 days, a twice per week i.p. injection of saline or 4 nmol/g TAT-Cx43266–283 was administered until neurological symptoms appeared. (D) Effect of TAT-Cx43266–283 on the survival of mice bearing orthotopic tumor syngrafts. Percentage of animals alive along the experiment depicted in Kaplan–Meier plot (n = 11 animals per condition from 3 independent experiments). Log-rank test **P < 0.01. (E) Representative images of the brains and tumor-bearing brain sections from control and treated animals at the end of the experiment. Bar: 1 mm.